National Health (Pharmaceutical Benefits) Regulations (Amendment) (Cth)

STATUTORY RULES

1970 No.

REGULATIONS UNDER THE NATIONAL HEALTH ACT 1953-1970.*

WHEREAS it is provided by sub-section (4.) of section 101 of the National Health Act 1953-1970 that a drug or medicinal preparation that was not a pharmaceutical benefit under the National Health Act 1953-1958 immediately before the commencement of that sub-section shall not be prescribed as a pharmaceutical benefit in accordance with section 85 of that Act unless the Pharmaceutical Benefits Advisory Committee has recommended to the Minister that it be so prescribed:

AND WHEREAS that Committee has recommended to the Minister that the following additional drugs and medicinal preparations be prescribed as pharmaceutical benefits under section 85 of the National Health Act 1953-1970, namely, the drugs and medicinal preparations inserted in the Third Schedule to the National Health (Pharmaceutical Benefits) Regulations by regulation 4 and the Second Schedule to these Regulations:

NOW THEREFORE I, THE GOVERNOR-GENERAL in and over the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the National Health Act 1953-1970.

Dated this twenty-ninth day of July, 1970.

Paul Hasluck

Governor-General.

By His Excellency's Command,

(SGD.) A. J. FORBES

Minister of State for Health.

Amendments of the National Health (Pharmaceutical Benefits) Regulations 

Commencement.

1. These Regulations shall come into operation on the first day of August, 1970.

First Schedule.

2. The First Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended—

(a) by inserting after item 12, the following item:—

" 12a. Antazoline Tablets ";

(b) by inserting after item 23, the following item:—

" 23aa. Bemegride Injection ";

(c) by inserting after item 76 the following items:—

" 76aa. Corticotrophin Injection

76ab. Corticotrophin Gelatin Injection

76ac. Corticotrophin Zinc Hydroxide Injection ";

* Notified in the Commonwealth Gazette on 1970.

  Statutory Rules 1960, No. 17, as amended by Statutory Rules 1960, Nos. 90 and 102; 1961, Nos. 59 and 137; 1962, Nos. 34, 101 and 114; 1963, Nos. 34, 69 and 107; 1964, Nos. 12, 57 and 135; 1965, Nos. 51, 151 and 152; 1966, Nos. 80 and 144; 1967, Nos. 67, 116 and 158; 1968, Nos. 44, 76, 88 and 146; 1969, Nos. 44, 107 and 185; and 1970, No.

16974/70—Price 20c  10/30.6.1970

(d) by omitting item 95; and

(e) by omitting item 418.

Second Schedule.

3. The Second Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in the First Schedule to these Regulations.

Third Schedule.

4. The Third Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in the Second Schedule to these Regulations.

Fifth Schedule.

5. The Fifth Schedule to the National Health (Pharmaceutical Benefits) Regulations is repealed and the following Schedule is inserted in its stead:—

FIFTH SCHEDULE  Regulation 14.

Pharmaceutical Benefits the Prescribing of Which is Subject to Conditions and Restrictions

     

First Column_Column	Third Column
	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
Item No.
1	Acetylcysteine.....................................................	Cystic Fibrosis (mucoviscidosis)
2	(1) Aspirin with Paracetamol and Caffeine Tablets	Any disease or condition in a pensioner
(2) Aspirin with Codeine Phosphate and Pentobarbitone Sodium Tablets
3	Acrylic Resin.....................................................	Ileostomy or colostomy conditions
4	Albumaid XP.....................................................	With the written authority of the Director-General, Phenylketonuria
5	Aldosterone.....................................................	With the written authority of the Director-General, treatment of an acute crisis in adrenal cortical hypofunction (including Addison's disease and salt-losing congenital adrenal hypoplasia)
6	Alprenolol Hydrochloride Injection	Idiopathic hypertrophic subaortic stenosis
Right ventricular outflow tract obstruction
Dissecting aneurysm, aortic
The treatment of angina in a patient who is frequently disabled by attacks of angina, in whom no evidence of cardiac failure is found and whose attacks of angina do not respond to other therapeutic agents except other beta-adrenergic receptor blocking agents
Serious arrhythmias
Thyrotoxicosis
7	Alprenolol Hydrochloride Tablets	With the written authority of the Director-General—
Idiopathic hypertrophic subaortic stenosis
Right ventricular outflow tract obstruction
Dissecting aneurysm, aortic
The treatment of angina in a patient who is frequently disabled by attacks of angina, in whom no evidence of cardiac failure is found and whose attacks of angina do not respond to other therapeutic agents except other beta-adrenergic receptor blocking agents
Serious arrhythmias
Thyrotoxicosis
8	Ambenonium Chloride.....................................................	Myasthenia gravis
9	Aminocaproic Acid.....................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
10	Aminosalicylic Acid.....................................................	Tuberculosis
11	Amphotericin B Injection.....................................................	Systemic mycoses
12	(1) Amphotericin B Tablets.....................................................	Moniliasis
(2) Amphotericin B Lozenges
(3) Amphotericin B Suspension

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
13	(1) Ampicillin Capsules, B.P	Infections of the ear or respiratory tract where they cannot be safely and effectively treated with sulphonamides, phenoxymethylpenicillin or phenethicillin
	(2) Ampicillin Injections, Tablets and Suspension
Gram-negative infections where ampicillin, appears to be the most suitable drug
Any bacterial infection of the genito-urinary tract which cannot be safely or effectively treated with sulphonamides
Broad spectrum antibiotic treatment of patients undergoing steroid therapy or recently subjected to steroid therapy
Pancreatitis
Meningitis
Any infection in a pregnant woman or a child that cannot be treated safely and effectively with sulphonamides, phenoxymethylpenicillin or phenethicillin
14	Ascorbic Acid Tablets, B.P......	Any disease or condition in a pensioner
15	Azathioprine	With the written authority of the Director-General, azathioprine therapy for a person who has been discharged from an approved hospital and received that therapy while a patient in the hospital
16	Beclamide..............................	Any disease or condition in a patient receiving treatment in or at an approved hospital
17	Benzathine Penicillin, B.P.......	Prophylaxis of recurrent streptococcal infections, (including rheumatic fever)
18	Benzoin Compound Tincture, B.P.C. aerosol spray	Ileostomy or colostomy conditions
19	Benzylpenicillin Injection, 5,000,000 units	Bacterial endocarditis or septicaemia
20	(1) Benzylpenicillin Tablets, B.P.	Prophylaxis of recurrent streptococcal infections,
(2) Benzylpenicillin Capsules	(including rheumatic fever)
21	Benzylpenicillin Injection,10,000,000 units	Bacterial endocarditis or septicaemia Gastrointestinal surgery
22	(1) Benzylpenicillin with Streptomycin Sulphate	Endocarditis due to streptococcus faecalis or streptococcus viridans
(2) Benzylpenicillin with Procaine Penicillin and Streptomycin Sulphate
23	Betahistine Hydrochloride	Meniere's Syndrome
24	(1) Betamethasone Acetate and Betamethasone Injection	Intra-articular use With the written authority of the Director-General,
(2) Betamethasone Sodium Phosphate Injection, B.P.	Pre-operative and post-operative prophylactic therapy for those patients undergoing or recently subjected to steroid therapy
25	Buclosamide with Salicylic Acid	For the treatment of diseases of the car
26	Buclosamide, Salicylic Acid and Hydrocortisone Acetate	For the treatment of diseases of the car
27	Busulphan Tablets, B.P...........	Treatment in malignant neoplasia
28	(1) Calciferol Tablets, Strong, B.P.	Any disease or condition in a pensioner
(2) Calciferol, B.P.	With the written authority of the Director-General—
Hypoparathyroidism
Osteomalacia following gastrectomy
Vitamin D-resistant rickets
29	Calcium Aminosalicylate........	Tuberculosis
30	Capreomycin Sulphate ............	Tuberculosis
31	Carbamazepine.......................	Epilepsy
Trigeminal neuralgia
32	Carbenicillin Sodium..............	With written authority of the Director-General, infections where positive bacteriological evidence confirms that carbenicillin is the most appropriate therapeutic agent

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
33	Carbenoxolone Sodium...............................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
34	Cephaloridine...............................................	With the written authority of the Director-General, infections where positive bacteriological evidence confirms that cephaloridine is the most appropriate therapeutic agent
35	Cephalothin Sodium...............................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
36	Charcoal Tablets...............................................	Ileostomy or colostomy conditions
37	Chlorambucil Tablets, B.P...............................................	Treatment in malignant neoplasia
38	Chloramine Deodorant Tablets and Powder	Ileostomy or colostomy conditions
39	(1) Chloramphenicol Capsules, B.P.	Bacterial meningitis
(2) Chloramphenicol Injections...............................................	Intraocular infections
(3) Chloramphenicol Oral Suspension	Rickettsioses
Typhoid
The treatment of other serious infections in a patient where it is established by appropriate bacteriological testing that Chloramphenicol is the only suitable antibiotic listed as a pharmaceutical benefit for use in treating the infection in the patient
40	Chlorotrianisene Tablets...............................................	Carcinoma of the prostate
41	(1) Chloropromazine Hydrochloride, B.P.	Any disease or condition in a pensioner
(2) Chlorpromazine Injection, B.P.	The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Chlorpromazine Hydrochloride, B.P., Chlorpromazine Injection, B.P. or Chlorpromazine Tablets, B.P.
(3) Chlorpromazine Tablets, B.P.
With the written authority of the Director-General—
Hereditary chorea (Huntington's)
Malignant neoplasia (late stage)
Radiation sickness
The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
42	Cholestyramine...............................................	With the written authority of the Director-General—
Pruritis associated with partial biliary obstruction not responding to other therapy
Initial treatment with cholestyramine of proven hyperbetalipoproteinaemia (type II) not responding to other therapy
A second or subsequent course of treatment for proven hyperbetalipoproteinaemia (type II) in patients who respond to treatment with cholestyramine but do not respond to other therapy
43	Clofibrate...............................................	With the written authority of the Director-General—
Diabetic retinopathy (exudative)
Initial treatment with clofibrate of hyperlipidaemia not responding to dietary therapy
A second or subsequent course of treatment for hyperlipidaemia where significant lowering of serum cholesterol subsequent to initial treatment with clofibrate has been established by laboratory report
44	(1) Cloxacillin Sodium, B.P...............................................	With the written authority of the Director-General, life threatening infection where bacteriological evidence confirms the presence of penicillinase-producing staphylococci
(2) Cloxacillin Capsules, B.P.

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
45	(1) Codeine Phosphate with Aspirin Soluble Tablets	Any disease or condition in a pensioner
(2) Codeine Phosphate with Aspirin Tablets
(3) Codeine Phosphate with Aspirin and Paracetamol soluble Tablets
(4) Codeine Phosphate with Aspirin and Paracetamol Tablets
(5) Codeine Phosphate with Aspirin, Paracetamol and Caffeine Tablets
46	Cod Liver Oil Emulsion.................................................	Any disease or condition in a child under the age of twelve years or in a pensioner
47	Colistin Sulphomethate Sodium, B.P., for injection	Pyocyaneus infection, other gram-negative infections where no other drug is effective
48	Cyanocobalamin Injection, B.P.................................................	Pernicious anaemia and other proven Vitamin B-12 deficiencies
Post gastrectomy treatment
Sub-acute combined degeneration of the cord
Neuroblastoma
49	(1) Cycloserine Tablets, B.P.................................................	Tuberculosis
(2) Cycloserine Capsules, B.P.
50	Cymogran............................................	With the written authority of the Director-General, phenylketonuria
51	(1) Cyproheptadine Hydrochloride, B.P.	Allergic rhinitis
Allergic dermatoses
(2) Cyproheptadine Tablets, B.P.
52	Cylosine Arabinoside Hydrochloride	Any disease or condition in a patient receiving treatment in or at an approved hospital
53	(1) Deodorant Detergent Solution (Terric N.8 with Spearmint Oil and Cetrimide)	Ileostomy or colostomy conditions
(2) Deodorant Detergent Solution (Lauryldimethyl Benzyl Ammonium Chloride and Terric N.8)
54	(1) Deoxycortone Acetate Injection, B.P.	Adrenal cortical hypofunction including Addison's disease
(2) Deoxycortone Privalate Injection, B.P.	Total adrenalectomy
(3) Deoxycortone Acetate Implants, B.P.
(4) Deoxycortone Acetate Tablets
55	Desferrioxamine.................................................	Acute iron poisoning
Hepatolenticular degeneration
56	Dexamethasone Sodium Phosphate Injections	Intra-articular use
Cerebral oedema
57	(1) Dextromoramide Tablets, B.P.	Treatment in malignant neoplasia
(2) Dextromoramide Tartrate, B.P.
58	Diazepam Injection.................................................	Any disease or condition in a pensioner
Electrical conversion of cardiac arrythmias (cardioversion)
Endoscopy
Epilepsy
Minor operative procedures
Motor neurone lesion
Premedication induction of anaesthesia
The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Diazepam

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
58—contd	With the written authority of the Director-General—
Hereditary chorea (Huntington's)
Malignant neoplasia (late stage)
Radiation sickness
The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
59	Diazepam Syrup and 10 mg. Tablet.................................................. s	Any disease or condition in a pensioner
Epilepsy
Motor neurone lesion
The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Diazepam
With the written authority of the Director-General—
Hereditary chorea (Huntington's)
Malignant neoplasia (late stage)
Radiation sickness
The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from air approved hospital
60	Diazepam Tablets 2 mg. and 5 mg.	Any disease or condition in a pensioner
Epilepsy
Motor neurone lesion
Multiple sclerosis
Stiff-man syndrome
The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Diazepam

With the written authority of the Director-General—
Hereditary chorea (Huntington's)
Malignant neoplasia (late stage)
Radiation sickness
The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
61	Dicyclomine Hydrochloride with Doxylamine Succinate and Pyridoxine Hydrochloride	Vomiting in pregnancy
62	Dienoestrol Cream..................................................	Any disease or condition in a pensioner
63	Diethanolamine Fusidate, B.P.C.	With the written authority of the Director-General, infections where positive bacteriological evidence confirms that Diethanolamine Fusidate is the only appropriate antibiotic that is listed as a benefit
64	(1) Dihydroergotoxine Mesylate tablets	For the treatment of patients who have suffered an attack of paralytic poliomyelitis
(2) Dihydroergotoxine Mesylate injection
65	Dihydrotachysterol.................................................. .	Hypoparathyroidism
66	Diloxanide Furoate Tablets, B.P.	Intestinal amoebiasis
67	Dimethicone Aerosol Spray..................................................	Ileostomy or colostomy conditions

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
68	Dimethicone Creams..................................................	Use with surgical appliances
69	Dioctyl Sodium Sulphosuccinate with Danthron	Any disease or condition in a pensioner
70	Disodium Cromoglycate..................................................	With the written authority of the Director-General—
The prevention of asthma for a patient who is under 18 years of age, whose attacks of asthma have been sufficiently severe and frequent to interfere seriously with his normal activities of life and whose re-occurrences of asthma could not be controlled by adequate use of bronchodilators and other standard means of prevention and treatment
The prevention of asthma for a patient whose attacks of asthma have been sufficiently severe and frequent to interfere seriously with his normal activities of life and to require the continuous use of over 7.5 mg. of prednisone, or its equivalent, daily or who suffers from a disease indicating that corticosteroid therapy should not be applied, such as peptic ulcer, hypertension of 180/100 or more before treatment, diabetes, osteoporosis proven by X-ray or steroid-induced myopathy
71	Ditophal..................................................	Leprosy
Lupus vulgaris
72	Droperidol..................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
73	(1) Erythromycin Estolate Capsules, B.P.	Amoebiasis
Brucellosis
(2) Erythromycin Estolate, B.P..................................................	Leptospirosis
(3) Erythromycin Tablets, B.P.	Lymphogranuloma venereum
(4) Erythromycin Ethyl Succinate	Pneumonia due to mycoplasma pneumoniae
(5) Erythromycin Glucoheptonate	Psittacosis
(6) Erythromycin Lactobionate..................................................	Rickettsioses
(7) Erythromycin Stearate, B.P..................................................	Staphylococcal septicaemia or staphylococcal pneumonia
(8) Erythromycin Stearate Tablets, B.P.
Actinomycosis, trachoma, or any bacterial or spirochaetal infections where these cannot be safely and effectively treated with sulphonamides, phenoxymethylpenicillin or phenethicillin
74	Ethacrynic Acid..................................................	Fluid retention associated with heart failure, cirrhosis of the liver or nephrotic syndrome
Fluid retention associated with other conditions and not responding to thiazides
75	Ethinyloestradiol Tablets, B.P..................................................	Any disease or condition in a pensioner
Carcinoma of the prostate
Hereditary telangiectasis
Premature menopause that is surgically induced
Turner's syndrome
76	Ethionamide..................................................	Tuberculosis
77	Ethisterone Tablets, B.P..................................................	Turner's syndrome
78	Ethyloestrenol..................................................	With the written authority of the Director-General—Intermittent use for corticosteroid-induced osteoporosis
Intermittent use for patients on long term treatment with corticosteroids
Osteomalacia following gastrectomy
79	Fludrocortisone Tablets, B.P..................................................	Adrenal cortical hypoplasia including Addison's disease
Total adrenalectomy
80	Flufenamic Acid..................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
81	Fluorouracil Sodium..................................................	Treatment in malignant neoplasia

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
82	Fluoxymesterone Tablets, B.P...................................................	Eunuchism
Eunuchoidism
Carcinoma of the breast
With the written authority of the Director-General— Intermittent use for corticosteroid-induced osteoporosis
Proven aplastic anaemias
83	Fluphenazine Enanthate..................................................	The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with either or both of the following pharmaceutical benefits—
Fluphenazine Enanthate
Fluphenazine Hydrochloride
With the written authority of the Director-General—
Hereditary chorea (Huntington's)
Malignant neoplasia (late stage)
Radiation sickness
The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
84	Fluphenazine Hydrochloride..................................................	Any disease or condition in a pensioner
The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with either or both of the following pharmaceutical benefits—
Fluphenazine Enanthate
Fluphenazine Hydrochloride
With the written authority of the Director-General—
Hereditary chorea (Huntington's)
Malignant neoplasia (late stage)
Radiation sickness
The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
85	(1) Folic Acid, B.P...................................................	Proven folic acid deficiency
(2) Folic Acid Tablets, B.P. 5 mg.	Sprue or the sprue-like syndrome
86	Folic Acid Tablets, B.P. 0.5 mg.	Pregnancy
87	Framycetin Sulphate Tablets..................................................	Bowel sterilization preparatory to major surgery
88	Frusemide Tablets, B.P..................................................	Fluid retention associatied with heart failure, cirrhosis of the liver or nephrotic syndrome
Fluid retention associated with other conditions and not responding to thiazides
89	Galactomin Formula No. 17..................................................	With the written authority of the Director-General—
Galactosaemia
Conditions needing an extreme restriction of lactose in the diet of a patient under the age of four years
90	Galactomin Formula No. 19..................................................	With the written authority of the Director-General, glucose-galactose malabsorption
91	Gentamicin Sulphate..................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
92	Glucose Indicator—Blood..................................................	With the written authority of the Director-General, diabetes mellitus in which adequate control is impossible by any other means because of low renal threshold

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
93	Goat's Milk, Dehydrated.....................................................	With the written authority of the Director-General, cow's milk allergy in children under the age of four years
94	Goat’s Milk, Whole (Sterilized).....................................................	With the written authority of the Director-General, cow's milk allergy in children under the age of four years
95	Griseofulvin Tablets, B.P......................................................	With the written authority of the Director-General, for use in severe tinea infections due to Microsporum, Trichophyton or Epidermophyton species which have been proven by laboratory examination or Wood's Light
96	Guanacline Tablets.....................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
97	Halibut Liver Oil Capsules.....................................................	Any disease or condition in a pensioner
98	Haloperidol.....................................................	Any disease or condition in a pensioner
The treatment of a mental disorder in a person who has after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Haloperidol
With the written authority of the Director-General—
Hereditary chorea (Huntington's)
Malignant neoplasia (late stage)
Radiation sickness
The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
99	(1) Hexachlorophane with Chloroxylenol	Any disease or condition in a patient receiving treatment in or at an approved hospital
(2) Hexachlorophane with Entsufon
(3) Hexachlorophane with Lissapol
(4) Hexachlorophane in Soap Solution
100	Hydrocortisone Acetate Injection, B.P.	Intra-articular use
101	Hydrocortisone Sodium Succinate Injection	Acute adrenal cortical hypofunction due to medical or surgical crisis
Prophylactic therapy before, during and after surgical procedures for patients undergoing or recently subjected to steroid therapy
Stevens-Johnson disease
102	Hydroxocobalamin Injection, B.P.	Pernicious anaemia and other proven Vitamin B-12 deficiencies
Post gastrectomy treatment
Sub-acute combined degeneration of the cord
Neuroblastoma
103	Hydroxyprogesterone Caproate.....................................................	Carcinoma of the endometrium
Progesterone deficiency proved by hormonal assay, by lateral wall smear or by endometrial biopsy
104	Idoxuridine.....................................................	Infections caused by Herpes Simplex Virus
105	Influenza Vaccine.....................................................	For prophylaxis of pensioners only
106	Insect Allergen Extract—Honey Bee	With the written authority of the Director-General, severe constitutional reaction to bee stings
107	Insect Allergen Extract—Paper Wasp	With the written authority of the Director-General, severe constitutional reaction to wasp stings
108	Isoniazid Tablets, B.P.....................................................	Tuberculosis
109	Isoprenaline Hydrochloride Tablets, 30 mg.	Stokes-Adams syndrome

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
110	Kanamycin Sulphate Capsules, injections and Oral Solution	With the written authority of the Director-General, infections where positive bacteriological evidence confirms that Kanamycin Sulphate is the most appropriate antibiotic
111	Kitasamycin...................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
112	Leucovorin...................................................	Antidote to folic acid antagonists
113	Levorphanol Tartrate ...................................................	Obstetrical use
Severe intractable pain
114	Lignocaine Injection, B.P...................................................	Cardiac arrhythmias
115	Lincomycin Hydrochloride...................................................	Gram positive coccal infections where these cannot be safely and effectively treated with penicillin and where resistance to erythromycin has been established by laboratory investigation
Osteomyelitis
116	Liothyronine Tablets, B.P...................................................	Myxoedema
117	Lofenalac ...................................................	With the written authority of the Director-General, phenylketonuria
118	Lypressin Nasal Spray...................................................	Diabetes insipidus
119	Maphenide Acetate...................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
120	Medroxyprogesterone Acetate Tablets, 2.5 mg.	Carcinoma of the endometrium
121	Medroxyprogesterone Acetate Tablets, 10 mg.	Carcinoma of the endometrium
Precocious puberty
122	Medroxyprogesterone Acetate Tablets, 100 mg.	Carcinoma of the breast
Carcinoma of the endometrium
Hypernephroma
123	Medroxyprogesterone Acetate Injections	Carcinoma of the endometrium
Hypernephroma
Progesterone deficiency proven by hormonal assay, by lateral wall smear or by endometrial biopsy
124	Melphalan...................................................	Treatment in malignant neoplasia
125	Mercaptopurine Tablets, B.P....................................................	Allergic granulomatous angiitis
Lupus erythematosus
Nephrotic syndrome
Periarteritis (Nodosa)
Treatment in malignant neoplasia
126	(1) Methandienone Tablets, B.P.	With the written authority of the Director-General—
(2) Methenolone Acetate	Intermittent use for corticosteroid-induced osteoporosis
Intermittent use for patients on long-term treatment with corticosteroids
127	Methicillin Sodium, B.P. for Injection	Proven or suspected staphylococcal septicaemia
128	Methotrexate Tablets...................................................	Treatment in neoplastic disease
129	Methotrexate Injections...................................................	Treatment in neoplastic disease
130	Methylprednisolone Acetate Injection	Intra-articular use
131	(1) Methyltestosterone Tablets, B.P.	Carcinoma of the breast
Eunuchism
(2) Methyltestosterone, B.P.	Eunuchoidism
Klinefelter's syndrome (seminiferous tubule dysgenesis)
132	Methysergide Maleate...................................................	Treatment of severe recalcitrant migraine where other treatment has failed
133	Metyrapone...................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
134	Minafen...................................................	With the written authority of the Director-General, phenylketonuria
135	Morphine Sulphate, B.P. with Tacrine Tablets	Severe intractable pain
136	Mustine Hydrochloride Injection	Treatment in malignant neoplasia

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Fart VII. of the Act
137	Nalidixic Acid....................................................	Urinary tract infections where positive bacteriological evidence shows sulphonamides to be ineffective
138	Nandrolone Decanoate....................................................	Carcinoma of the breast
With the written authority of the Director-General—
Intermittent use for corticosteroid-induced osteoporosis
Intermittent use for patients on long-term treatment with corticosteroids
Severe osteoporosis due to proven pancreatitis
139	Nandrolone Hexoxyphenyl Propionate	Carcinoma of the breast
With the written authority of the Director-General— Intermittent use for corticosteroid-induced osteoporosis
Intermittent use for patients on long-term treatment with corticosteroids
140	Nandrolone Phenylpropionate Injection, B.P.	Carcinoma of the breast
With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis
141	(1) Natamycin Oral Tablets....................................................	Moniliasis

(2) Natamycin Oral Suspension....................................................
142	Neomycin Sulphate Powder....................................................	With the written authority of the Director-General, use by inhalation in cystic fibrosis (mucoviscidosis)
143	Neomycin Tablets, B.P.....................................................	Bowel sterilization preparatory to major surgery
Encephalopathy, hepatic
144	Nicotinic Acid Tablets, B.P.....................................................	Any disease or condition in a pensioner
145	Nitrazepam ....................................................	Myoclonic epilepsy
146	(1) Nitrofurantoin Tablets, B.P.....................................................	Urinary tract infections where positive bacteriological evidence shows sulphonamides to be ineffective
(2) Nitrofurantoin Oral Suspension
147	Nitromin....................................................	Treatment in malignant neoplasia
148	Norethisterone Acetate, B.P. ....................................................	Carcinoma of the breast
149	Nutramigen ....................................................	With the written authority of the Director-General—
Cow's milk allergy in children under the age of four years
Cystic Fibrosis (mucoviscidosis)
Galactosaemia
Lactose intolerance
150	Nystatin Tablets, B.P................................................	Moniliasis
151	Orciprenaline Sulphate Injection....................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
152	Oxprenolol Hydrochloride Tablets, 20 mg and 40 mg	With the written authority of the Director-General—
Idiopathic hypertrophic subaortic stenosis
Right ventricular outflow tract obstruction
Dissecting aneurysm, aortic
The treatment of angina in a patient who is frequently disabled by attacks of angina, in whom no evidence of cardiac failure is found and whoso attacks of angina do not respond to other therapeutic agents except other beta-adrenergic receptor blocking agents
Serious arrhythmias
Thyrotoxicosis
153	Oxprenolol Hydrochloride Injection	Idiopathic hypertrophic subaortic stenosis
Right ventricular outflow tract obstruction
Dissecting aneurysm, aortic
The treatment of angina in a patient who is frequently disabled by attacks of angina, in whom no evidence of cardiac failure is found and whoso attacks of angina do not respond to other therapeutic agents except other beta-adrenergic receptor blocking agents
Serious arrhythmias
Thyrotoxicosis

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
154	Oxycodone Pectinate...............................................	Treatment in malignant neoplasia
155	Oxymetholone...............................................	With the written authority of the Director-General, proven aplastic or hypoplastic anaemias (familial)
156	(1) Pancreatin, B.P................................................	Cystic Fibrosis (mucoviscidosis)
(2) Pancreatin Enzyme 4 X U.S.N.F. XII	Following pancreatico-duodenectomy
	Pancreatic steatorrhoea
(3) Pancrelipase
157	(1) Paracetamol Suspension...............................................	Any disease or condition in a pensioner
(2) Paracetamol Tablets, B.P.
158	Paracetamol with Codeine Phosphate and Pentobarbitone Sodium	Any disease or condition in a pensioner
155	(1) Paraffin Liquid Emulsion...............................................	Any disease or condition in a pensioner
(2) Paraffin Liquid Emulsion with Phenolphthalein
160	Pargyline Hydrochloride...............................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
161	Penicillamine...............................................	With the written authority of the Director-General—
Acute heavy metal intoxication
Cystinosis
Cystinuria with calculus formation
Haemoglobinuria, paroxysmal cold
Wilson's disease (hepatolenticular degeneration)
162	Pethidine Hydrochloride with Levallorphan Tartrate	Obstetric use
163	Phytomenadione Injection, B.P., 10 mg. per ml.	Antidote to anticoagulants
Haemorrhagic diathesis associated with malabsorption
164	Phytomenadione Injection, B.P., 1 mg. in 1 ml.	Antidote to anticoagulants
Suspected cerebral trauma of the new born
Haemorrhagic diathesis associated with malabsorption
Haemorrhagic disease of the new born
165	Pituitary, Posterior Lobe, Insufflation	Diabetes insipidus
166	Plasma Substitute (Polypeptide)...........................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
167	Polymyxin B. Sulphate Powder...............................................	With the written authority of the Director-General, use by inhalation in cystic fibrosis (mucoviscidosis)
168	Polyocstradiol Phosphate...............................................	Carcinoma of the breast
Carcinoma of the prostate
169	Prednisolone Sodium Phosphate	With the written authority of the Director-General—
Retention Enema and Suppository	Ulcerative colitis proven by sigmoidoscopy or radiological report
Proctitis proven by sygmoidoscopy
170	(1) Prednisolone Acetate Injection	Intra-articular use
(2) Prednisolone Butyl Acetate Injection
171	Prednisolone Sodium Succinate Injection	Acute adrenal cortical hypofunction due to any medical or surgical crises
Prophylactic therapy before, during and after surgical procedures for patients undergoing or recently subject to steroid therapy
Stevens-Johnson disease
172	Procarbazine Hydrochloride...............................................	Treatment in malignant neoplasia
173	(1) Prochlorperazine...............................................	Meniere's Syndrome
(2) Prochlorperazine Tablets, B.P.
174	Progesterone...............................................	Progesterone deficiency proven by hormonal assay, by lateral wall smear or by endometrial biopsy
175	Propranolol Injection, B.P...............................................	Idiopathic hypertrophic subaortic stenosis
Right ventricular outflow tract obstruction
Dissecting aneurysm, aortic

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
175—contd	The treatment of angina in a patient who is frequently disabled by attacks of angina, in whom no evidence of cardiac failure is found and whose attacks of angina do not respond to other therapeutic agents except other beta-adrenergic receptor blocking agents
Serious arrhythmias
Thyrotoxicosis
176	Propranolol Tablets, B.P...................................................	With the written authority of the Director-General—
Idiopathic hypertrophic subaortic stenosis
Right ventricular outflow tract obstruction
Dissecting aneurysm, aortic
The treatment of angina in a patient who is frequently disabled by attacks of angina, in whom no evidence of cardiac failure is found and whose attacks of angina do not respond to other therapeutic agents except other beta-adrenergic receptor blocking agents
Serious arrhythmias
Thyrotoxicosis
177	Prosobee..................................................	With the written authority of the Director-General—
Galactosaemia
Homocystinuria
Lactose intolerance
Milk allergy in children under the age of four years
178	Pyrazinamide..................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
179	(1) Pyridostigmine Injection, B.P.	Myasthenia gravis
(2) Pyridostigmine Tablets, B.P.
180	Pyridoxine Hydrochloride Tablets	Homocystinuria
Radiation sickness
Treatment and prophylaxis of peripheral neuritis caused or likely to be caused by isoniazid therapy
Sideroblastic (refractory anaemia)
181	Pyrimethamine Tablets..................................................	Toxoplasmosis
Malaria
182	(1) Riboflavine Tablets............................................	Any disease or condition in a pensioner
(2) Senna Fruit Extract (standardised)
183	Sobee..................................................	With the written authority of the Director-General—
Galactosaemia
Homocystinuria
Lactose intolerance
Milk allergy in children under the age of four years
184	(1) Sodium Aminosalicylate Tablets, B.P.	Tuberculosis
(2) Sodium Aminosalicylate Injection
(3) Sodium Aminosalicylate Cachets
(4) Sodium Aminosalicylate Granules
(5) Sodium Aminosalicylate with Isoniazid, B.P.
185	Sodium Folate..................................................	Proven folic acid deficiency
Sprue or the sprue-like syndrome
186	Sodium Fusidate..................................................	With the written authority of the Director-General, infections where positive bacteriological evidence confirms that Sodium Fusidate is the only appropriate antibiotic that is listed as a benefit
187	Soyalac..................................................	With the written authority of the Director-General—
Galactosaemia
Homocystinuria
Lactose intolerance
Milk allergy in children under the age of four years

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
188	Spiramycin...................................................	Staphylococcal septicaemia or staphylococcal pneumonia
Toxoplasmosis, active-serologically proven
Any gram-positive bacterial infections where these cannot be treated safely and effectively by sulphonamides or penicillins
189	Spironolactone Tablets, B.P....................................................	With the written authority of the Director-General—
To supplement other diuretics when these have proved inadequate
Myasthenia gravis
190	Stanolone...................................................	Carcinoma of the breast
With the written authority of the Director-General—
Intermittent use for corticosteroid-induced osteoporosis
Intermittent use for patients on long-term treatment with corticosteroids
191	Stanozolol................................................... .	With the written authority of the Director-General—
Intermittent use for corticosteroid-induced osteoporosis
Intermittent use for patients on long-term treatment with corticosteroids
192	Stilboestrol Diphosphate...................................................	Carcinoma of the prostate
193	Streptokinase...................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
194	Sulphasalazine...................................................	Ulcerative colitis
195	Sulthiame...................................................	Epilepsy where other anticonvulsants have failed
196	(1) Surgical Cement...................................................	Ileostomy or colostomy conditions
(2) Surgical Cement Solvent	For use with surgical appliances
197	(1) Sustanon...................................................	Eunuchoidism
Eunuchism
(2) Testosterone Implants, B.P.	Klinefelter's syndrome (seminiferous tubule dysgenesis)
(3) Testosterone Enanthate
(4) Testosterone Propionate Injection, B.P.	Carcinoma of the breast
198	Tetanus Antitoxin, B.P. (Bovine)	Patients who have previously received an injection of equine serum
199	(1) Thiambutosine Tablets, B.P....................................................	Leprosy
(2) Thiambutosine Injection
200	Thiamine Hydrochloride Tablets, B.P.	Any disease or condition in a pensioner
201	Thiethylperazine Tablets and Suppositories	Radiation sickness
Nausea resulting from cytotoxic therapy
202	(1) Thioridazine Tablets, B.P....................................................	Any disease or condition in a pensioner
(2) Thioridazine	The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with either or both of the following pharmaceutical benefits—
Thioridazine
Thioridazine Tablets, B.P.
With the written authority of the Director-General—
Hereditary chorea (Huntington's)
Malignant neoplasia (late stage)
Radiation sickness
The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
203	Thyrotrophin...................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
204	Tragacanth, Indian (Gum Karaya)	Ileostomy or colostomy conditions

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
205	Trasylol.........................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
206	Tretamine…………………………	Treatment in malignant neoplasia
207	Triacetylolcandomycin……………	Amoebiasis
Brucellosis
Leptospirosis
Lymphogranuloma venereum
Pneumonia due to mycoplasma pneumoniae
Pneumonia, staphylococcal
Psittacosis
Rickettsioses
Staphylococcal septicaemia
Actinomycosis, Trachoma, or any bacterial or spirochetal infections where these cannot be safely and effectively treated by sulphonamides, phenoxymethylpenicillin or phenethicillin
208	(1) Trifluoperazine Tablets, B.P…	Any disease or condition in a pensioner
(2) Trifluoperazine Hydrochloride, B.P.	The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Trifluoperazine Hydrochloride, B.P. or Trifluoperazine Tablets, B.P.
With the written authority of the Director-General—
Hereditary chorea (Huntington's)
Malignant neoplasia (late stage)
Radiation sickness
The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
209	Triglyde…………………………….	With the written authority of the Director-General, proven malabsorption
210	Trimetaphan Injection, B.P………..	Hypotensive in anaesthesia
211	Trimethoprim with Sulphamethox-azole	Any disease or condition in a patient receiving treatment in or at an approved hospital
212	Vadrine……………………………	Any disease or condition in a patient receiving treatment in or at an approved hospital
213	Velactin……………………………	With the written authority of the Director-General—
Galactosaemia
Homocystinuria
Lactose intolerance
Milk allergy in children under the age of four years
214	(1) Vinblastine Sulphate	Treatment in malignant neoplasia
(2) Vincristine Sulphate
215	Vinyl Pyrrolidone and Vinyl Acetate with Benzocaine Aerosol Spray	Ileostomy or colostomy conditions
216	(1) Viomycin Sulphate ...................	Tuberculosis
(2) Viomycin Sulphate Injection, B.P.
217	Vitamin A with Thiamine Hydrochloride, Riboflavine, Nicotinamide, Ascorbic Acid and Vitamin D Tablets and Capsules	Any disease or condition in a pensioner

THE SCHEDULES

FIRST SCHEDULE  Regulation 3.

Amendments of the Second Schedule to the National Health (Pharmaceutical Benefits) Regulations

1. Add at the end of item 13 (in the third column)—

" Ferrous Sulphate mixture Prescribers' Lis

Ferrous Sulphate mixture Prescribers' List, Children's Section ".

2. Add at the end of item 91 (in the third column)—

" Neomycin Sulphate with Nystatin, Triamcinolone Acctonide and Gramicidin ".

3. Add at the end of item 95 (in the third column)—

" Natamycin with Neomycin Sulphate and Hydrocortisone ".

4. Insert in item 125 (in the third column)—

" Neomycin Sulphate with Hydrocortisone and Natamycin ".

5. Add at the end of item 126 (in the third column)—

" Gramicidin with Nystatin, Triamcinolone Acctonide and Neomycin Sulphate Natamycin with Hydrocortisone and Neomycin Sulphate ".

6. Add at the end of item 133 (in the third column)—

" Gramicidin with Neomycin Sulphate, Triamcinolone Acctonide and Nystatin ".

7. After item 203 insert—

" 203a Triamcinolone Acetonide................................................. Gramicidin with Neomycin Sulphate, Nystatin and Triamcinolone Acetonide ".

SECOND SCHEDULE  Regulation 4.

Amendments of the Third Schedule to the National Health (Pharmaceutical Benefits) Regulations

1. Omit item 75, insert—

" 75. Carbenicillin Sodium ".

2. After item 80, insert—

" 80a. Cephalothin Sodium ".

3. After item 91, insert—

" 91a. Cholestyramine ".

4. Omit item 117, insert—

" 117. Desferrioxamine Mesylate ".

5. Omit item 136.

6. Omit item 165.

7. After item 186, insert—

" 187. Hemodialysis Fluid—Concentrate ".

8. After item 197, insert—

" 197a. Insect Allergen Extract—Paper Wasp ".

9. After item 215, insert—

" 215a. Leucovorin ".

10. After item 223a, insert—

" 223b. Mebeverine Hydrochloride ".

11. Omit item 266a, insert—

" 266a. Oxprenolol Hydrochloride ".

12. Omit items 309 and 310.

13. After item 359, insert—

" 359a. Stilboestrol Diphosphate ".

14. After item 405, insert—

" 405a. Trimipramine Maleate

405b. Trimipramine Mesylate ".

Printed by Authority by the Government Printer of the Commonwealth of Australia